CD4 and lung cancer: We firstly evaluated all the 303 lung cancer patients in this study, the results showed that CD3, CD4, CD8, and CD16 + 56+ T cells were significantly decreased in the ATB group (n = 145) than that in the non-ATB group (n = 158) (p < 0.01).